440 related articles for article (PubMed ID: 34511919)
1. Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review.
Ruangritchankul S; Chantharit P; Srisuma S; Gray LC
Ther Clin Risk Manag; 2021; 17():927-949. PubMed ID: 34511919
[TBL] [Abstract][Full Text] [Related]
2. Early intervention and adding effective doses of EGb761 like
Özge A; Ghouri R; Öksüz N; Taşdelen B
Front Neurol; 2023; 14():1240655. PubMed ID: 38156089
[TBL] [Abstract][Full Text] [Related]
3. Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study.
Chen S; Price AC; Cardinal RN; Moylett S; Kershenbaum AD; Fitzgerald J; Mueller C; Stewart R; O'Brien JT
PLoS Med; 2022 Dec; 19(12):e1004124. PubMed ID: 36472984
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson's disease and acetylcholinesterase inhibitors in Parkinson's disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data.
Baik D; Yu YM; Jung SY; Kang HY
BMC Geriatr; 2022 Jul; 22(1):609. PubMed ID: 35864474
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
Cacabelos R
Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):673-701. PubMed ID: 32520597
[TBL] [Abstract][Full Text] [Related]
6. Acetylcholinesterase inhibitors reduce spreading activation in dementia.
Foster PS; Branch KK; Witt JC; Giovannetti T; Libon D; Heilman KM; Drago V
Neuropsychologia; 2012 Jul; 50(8):2093-9. PubMed ID: 22609576
[TBL] [Abstract][Full Text] [Related]
7. Use of Drugs With Risk of Heart Rate-Related Problems is Common in Norwegian Dementia Patients Treated With Acetylcholinesterase Inhibitors: A Prevalence Study Based on the Norwegian Prescription Database.
Efjestad AS; Ihle-Hansen H; Hjellvik V; Engedal K; Blix HS
Front Pharmacol; 2021; 12():791578. PubMed ID: 35273492
[No Abstract] [Full Text] [Related]
8. Adverse drug reactions in older adults: a narrative review of the literature.
Zazzara MB; Palmer K; Vetrano DL; Carfì A; Onder G
Eur Geriatr Med; 2021 Jun; 12(3):463-473. PubMed ID: 33738772
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
10. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial.
Youn H; Lee KJ; Kim SG; Cho SJ; Kim WJ; Lee WJ; Hwang JY; Han C; Shin C; Jung HY
Psychiatry Investig; 2021 Mar; 18(3):233-240. PubMed ID: 33685036
[TBL] [Abstract][Full Text] [Related]
11. Methodological framework to identify possible adverse drug reactions using population-based administrative data.
Sauer B; Nebeker J; Shen S; Rupper R; West S; Shinogle JA; Xu W; Lohr KN; Samore M
F1000Res; 2014; 3():258. PubMed ID: 26180631
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions in elderly patients with cognitive disorders: A systematic review.
Kanagaratnam L; Dramé M; Trenque T; Oubaya N; Nazeyrollas P; Novella JL; Jolly D; Mahmoudi R
Maturitas; 2016 Mar; 85():56-63. PubMed ID: 26857880
[TBL] [Abstract][Full Text] [Related]
13. Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
Cacabelos R
Neuropsychiatr Dis Treat; 2007 Jun; 3(3):303-33. PubMed ID: 19300564
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Combination Treatment with Citicoline in Dementia.
Gareri P; Veronese N; Cotroneo AM
Rev Recent Clin Trials; 2022; 17(1):4-8. PubMed ID: 34939548
[TBL] [Abstract][Full Text] [Related]
15. Risk for Health Events After Deprescribing Acetylcholinesterase Inhibitors in Nursing Home Residents With Severe Dementia.
Niznik JD; Zhao X; He M; Aspinall SL; Hanlon JT; Hanson LC; Nace D; Thorpe JM; Thorpe CT
J Am Geriatr Soc; 2020 Apr; 68(4):699-707. PubMed ID: 31769507
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N
Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552
[TBL] [Abstract][Full Text] [Related]
17. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
